<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2849132&amp;fmt=gif">
Solution_Eyebrow

Microsegmentation Solution Brief for BioTech & Pharma

Learn how to achieve FDA-compliant zero trust microsegmentation for pharmaceutical manufacturing and lab environments. This guide provides clear implementation steps for protecting critical drug formulas, clinical trial data, and production systems without disrupting 24/7 operations.

Read the Solution Brief
Pharmaceutical Lab Network Security
Solution-Brief-Pharma-card-reveal
Download_Eyebrow

Get Your Comprehensive Elisity Solution Guide for BioTech & Pharma Microsegmentation

Deepen your understanding of Elisity's identity-centric microsegmentation platform for pharmaceutical environments, including FDA compliance frameworks, rapid implementation strategies, and proven approaches for protecting manufacturing systems while ensuring continuous production of life-saving treatments.

  • Why FDA's new OT cybersecurity guidance mandates network segmentation as a critical control
  • How Elisity's identity-centric architecture decouples access from network infrastructure for pharmaceutical environments
  • Implementation roadmap showing deployment in weeks using your existing Cisco, Juniper, Aruba, Hirschmann or Arista switches.
  • Why GSK, Andelyn Biosciences, and global pharmaceutical enterprises trust Elisity for manufacturing security.
Download Here
Small_Logo
Andelyn_Feature
Eyebrow_Customer_Spotlight

‟I can't speak highly enough about that initial engagement... when we went forward with this and the first couple of days, the ease of implementation and getting to a point of being able to create and implement the policies was something, you know, unheard of.”

—Bryan Holmes, Director of IT Security at Andelyn Biosciences
Eyebrow

What is Microsegmentation?

Identity-based microsegmentation applies granular least-privilege policies to protect pharmaceutical IP, manufacturing systems, and lab equipment from lateral movement attacks. Implement it rapidly using existing infrastructure without requiring new agents, hardware, or production downtime that could disrupt critical drug manufacturing.

Event_Info_Eyebrow

Why Pharmaceutical Security Cannot Wait


  • Attackers leverage lateral movement in over 70% of successful pharmaceutical breaches, targeting valuable drug formulas and clinical trial data
  • FDA 21 CFR Part 11, IEC 62443, and cyber insurers are mandating network segmentation as a critical control for pharmaceutical manufacturers in 2025
  • Traditional microsegmentation projects become complex, never-ending initiatives that risk disrupting 24/7 production of life-saving treatments
  • Gene therapy production disruptions directly impact patient lives, making rapid, non-disruptive security implementation essential
Elisity Implementation Timeline
Integrations-Overview-Hero-Platform-2
Download_Eyebrow

The Business Value of Elisity's Microsegmentation Platform

  • Rapid deployment without production disruption using Elisity's identity-centric architecture that works with your existing switching infrastructure—no new agents, hardware, VLANs, or ACLs required
  • "No-fear" policy creation with Elisity's Cloud Control Center enabling policy simulation before enforcement, ensuring no risk to critical drug production batches
  • Reduce cyber insurance premiums by 20%+ while maintaining continuous manufacturing through Elisity's dynamic policies that adapt as FDA guidance changes
  • Real-time containment preserving drug production with faster incident response through Elisity's IdentityGraph™ and automated policy enforcement
Download Here